TABLE 4.
Literature reports on the associations between tumour‐associated macrophages (TAMs) and the prognosis of gastric cancer (GC) patients.
| Study result | Marker in TAMs | Sample size (case) | References |
|---|---|---|---|
| The higher expression of CD68 or CD206 predicts poorer survival outcomes in HER2‐positive GC patients, while the higher expression of CD86 indicates a better prognosis |
Total TAMs: CD68 M1 TAMs: CD86 M2 TAMs: CD206 |
33 | 16 |
| Patients with high CD204 TAMs infiltration had a shorter 5‐year survival time of GC | M2 TAMs: CD204 | 228 | 40 |
| The GC patients with high CD163 expression exhibited poor OS, compared with patients expressing low levels of CD163 | M2 TAMs: CD163 | 60 | 83 |
| GC patients with a higher expression of CD68 had a shorter OS when compared with patients with a lower expression of CD68 | Total TAMs: CD68 | 60 | 113 |
| GC patients with high infiltration of CD163 TAMs in tumour stroma and invasive tumour margin were significantly correlated with poor OS | M2 TAMs: CD163 | 113 | 124 |
| The high CD11c expression was a prognosticator for better OS in GC patients | M1 TAMs: CD11c | 433 | 128 |
| In a univariate analysis of outcome, M2 TAMs within the core were associated with improved RFS, but not OS. GC patients with a higher effective density of M2 TAMs (0−10 μm) had significantly longer RFS and OS when compared with patients with lower TAM density |
Total TAMs: CD68+ and AE1AE3− M1 TAMs: CD68+, CD163− and CD206− M2 TAMs: CD68+, CD163+ or CD206+ |
51 | 129 |
| GC patients with high infiltration of SIGLEC10‐positive TAMs usually predicted worse OS | SIGLEC10 | 134 | 131 |
| GC patients with high expression of CD68, CD163 or CD47 predicted worse OS |
Total TAMs: CD68 M2 TAMs: CD163 |
423 | 157 |
| GC patients with high expression of C5aR1‐positive TAMs indicated poor OS and worse response to 5‐fluorouracil | C5aR1 | 459/342 | 158 |
| GC patients with high infiltration of Dectin‐1‐positive TAMs usually predicted worse OS and DFS | Dectin‐1 | 451 | 159 |
| High infiltration of M1 TAMs predicted better OS in GC patients with stage IV | M1 TAMs: IL‐18 | 94 | 162 |
| A low density of CD163 TAMs was significantly associated with poor DFS in microsatellite instability‐high GC patients |
Total TAMs: CD68 M2 TAMs: CD163 |
143 | 167 |
| High versus low CD11c density and low versus high CD206 density indicated better OS in GC patients |
Total TAMs: CD68 M1 TAMs: CD11c M2 TAMs: CD206 |
180 | 168 |
| GC patients with high M1 density or M1/M2 ratio had a higher OS compared with those with low M1 density or M1/M2 ratio |
M1 TAMs: CD68 and NOS2 M2 TAMs: CD68 and CD163 |
52 | 169 |
Abbreviations: DFS, disease‐free survival; IL, interleukin; OS, overall survival; RFS, relapse‐free survival.